Enzalutamide bulk supplier for pharma manufacturers

Enzalutamide Suppliers & Bulk Manufacturers

Available Forms: Tablet & Capsule

Available Strengths: Capsules- 40 mg, Tablet - 40 mg & 80 mg

Reference Brands: Xtandi® (EU & US)

Enzalutamide is an androgen receptor inhibitor for prostate cancer, both hormone-sensitive and castration-resistant, taken once daily as 40 mg capsules or 40 mg and 80 mg tablets. The originator is Xtandi (Astellas/Pfizer); generic versions are sold in some markets while patents still apply in others. Patent status differs by country, so we confirm what can lawfully be supplied to your destination before quoting.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Enzalutamide? List it or send an offer →

Product Description: Enzalutamide is a next-generation androgen receptor inhibitor indicated for the treatment of prostate cancer, including metastatic castration-resistant and non-metastatic castration-resistant forms. Marketed as Xtandi®, it is available in 40 mg capsules and 40 mg/80 mg tablets in both the US and EU. It works by blocking androgen signaling pathways, helping slow disease progression. With proven clinical benefits and oral administration, Enzalutamide represents a high-value B2B oncology opportunity for pharmaceutical partners targeting the oncology segment in regulated markets such as the EU and United States.

Enzalutamide — third party manufacturing & bulk supply

Enzalutamide is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Enzalutamide is supplied as Tablet & Capsule — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Enzalutamide listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Enzalutamide →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing